Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA, Palmieri G. Colombino M, et al. Among authors: mozzillo n. J Clin Oncol. 2012 Jul 10;30(20):2522-9. doi: 10.1200/JCO.2011.41.2452. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614978
Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma.
Palmieri G, Satriano SM, Budroni M, Cossu A, Tanda F, Canzanella S, Caracò C, Simeone E, Daponte A, Mozzillo N, Comella G, Castello G, Ascierto PA. Palmieri G, et al. Among authors: mozzillo n. BMC Cancer. 2006 Nov 15;6:266. doi: 10.1186/1471-2407-6-266. BMC Cancer. 2006. PMID: 17107608 Free PMC article.
Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay.
Palmieri G, Ascierto PA, Cossu A, Mozzillo N, Motti ML, Satriano SM, Botti G, Caracò C, Celentano E, Satriano RA, Lissia A, Tanda F, Pirastu M, Castello G; Melanoma Cooperative Group. Palmieri G, et al. Among authors: mozzillo n. J Clin Oncol. 2001 Mar 1;19(5):1437-43. doi: 10.1200/JCO.2001.19.5.1437. J Clin Oncol. 2001. PMID: 11230489
Prognostic value of CD40 in adult soft tissue sarcomas.
Ottaiano A, De Chiara A, Perrone F, Botti G, Fazioli F, De Rosa V, Mozzillo N, Ravo V, Morrica B, Gallo C, Pisano C, Napolitano M, Ascierto PA, Iaffaioli RV, Apice G. Ottaiano A, et al. Among authors: mozzillo n. Clin Cancer Res. 2004 Apr 15;10(8):2824-31. doi: 10.1158/1078-0432.ccr-0139-03. Clin Cancer Res. 2004. PMID: 15102691
The role of spectrophotometry in the diagnosis of melanoma.
Ascierto PA, Palla M, Ayala F, De Michele I, Caracò C, Daponte A, Simeone E, Mori S, Del Giudice M, Satriano RA, Vozza A, Palmieri G, Mozzillo N. Ascierto PA, et al. Among authors: mozzillo n. BMC Dermatol. 2010 Aug 13;10:5. doi: 10.1186/1471-5945-10-5. BMC Dermatol. 2010. PMID: 20707921 Free PMC article. Clinical Trial.
Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.
Ascierto PA, Daponte A, Parasole R, Perrone F, Caracò C, Melucci M, Palmieri G, Napolitano M, Mozzillo N, Castello G. Ascierto PA, et al. Among authors: mozzillo n. Cancer. 2000 Oct 1;89(7):1490-4. doi: 10.1002/1097-0142(20001001)89:7<1490::aid-cncr11>3.0.co;2-v. Cancer. 2000. PMID: 11013362 Clinical Trial.
154 results